Pfizer Acquires Rinat Neuroscience Corp.
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Genomics, Proteomics and Bioinformatics by ruth on April 13, 2006

"Rinat is a pioneer in developing protein-based therapeutics and we see tremendous potential in its research to develop new medicines, notably for the treatment of Alzheimer's disease. Combining Rinat's potential product portfolio with Pfizer's capabilities is a further step in our strategy to enhance Pfizer's internal research and development efforts with high-potential, externally sourced product candidates and technologies."
Some of the compounds in Rinat's pipeline are RN624, a nerve growth factor inhibitor for treatment of acute and chronic pain (currently entering Phase II clinical trials) and RN1219, a humanized monoclonal antibody
for the potential treatment of Alzheimer's disease.Permalink: Pfizer Acquires Rinat Neuroscience Corp.
Tags:
alzheimer
acquisition
biotech
rinat
pfizer
neuroscience+corp
rinat+neuroscience
pfizer+acquires
Trackback: http://www.creative-weblogging.com/cgi-bin/mt-tb.pl/20024

Mr Wong
